Traditional US Obesity Programs Have Failed Us – But New Science Provides Hope and a Path Forward
There is an intense media focus on the arrival of a new class of Anti Obesity Medications (AOMs) and a robust national discussion to clarify their value (“bang for the buck”) given the mix of positives (significant clinical benefits) and negatives (side effects, weight regain on stopping, and high price tag). This is the first …
